308
Participants
Start Date
January 1, 2025
Primary Completion Date
April 1, 2029
Study Completion Date
April 1, 2029
Baricitinib (LY3009104) 4 mg
"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"
filgotinib 200mg/day
"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"
Tofacitinib 5 mg twice daily
"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"
Upadacitinib 15 MG
"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"
Baricitinib (LY3009104) 4 mg
use of JAK inhibitor at full dose until the end of the protocol
filgotinib 200mg/day
use of JAK inhibitor at full dose until the end of the protocol
Tofacitinib 5 mg twice daily
use of JAK inhibitor at full dose until the end of the protocol
Upadacitinib 15 MG
use of JAK inhibitor at full dose until the end of the protocol
University Hospital, Toulouse
OTHER